SAGE-689 is under clinical development by Sage Therapeutics and currently in Phase I for Unspecified Central Nervous System Disorders. According to GlobalData, Phase I drugs for Unspecified Central Nervous System Disorders have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SAGE-689’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SAGE-689 overview
SAGE-689 is under development for the treatment of disorders associated with acute GABA hypofunction. The drug candidate is administered by intramuscular. It is a new chemical entity (NCE) that targets GABAA receptors. It is developed based on positive and negative allosteric modulator (PANAM) chemistry platform, which comprises of non-benzodiazepine approach that regulates allosteric modulation of GABAA receptor in the positive (PAM) direction. The drug candidate was also under development for neuroanesthesia, refractory status epilepticus (SE) as an adjunctive therapy and for unspecified indication.
Sage Therapeutics overview
Sage Therapeutics (Sage) is a clinical-stage biopharmaceutical company that discovers, develops and markets drugs for the treatment of central nervous system (CNS) disorders. It develops drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors of NMDA and GABA. Its flagship product Zulresso (brexanolone) is a proprietary intravenous (IV) formulation administered for the treatment of postpartum depression (PPD). The company also has various pipeline products for the treatment of indications such as major depressive disorders, bipolar depression, Parkinson’s disease, insomnia, epileptiform disorders, and NMDA hypofunction. The company operates in the US, Bermuda, Germany, Switzerland, Scotland, England, and Wales through its subsidiaries. Sage is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of SAGE-689’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
